Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00256100




Registration number
NCT00256100
Ethics application status
Date submitted
17/11/2005
Date registered
21/11/2005
Date last updated
12/04/2017

Titles & IDs
Public title
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.
Scientific title
Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.
Secondary ID [1] 0 0
2004.066
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Renal Failure 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fondaparinux Sodium

Active Comparator: One - Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study

Active Comparator: Two - Fondaparinux will be used as the anticoagulant in the sencond arm of the study


Treatment: Drugs: Fondaparinux Sodium
The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to the current standard haemofilter anticoagulant, enoxaparin.
Timepoint [1] 0 0
Duration of the haemofilter life
Secondary outcome [1] 0 0
To assess the incidence of complications, primary bleeding with fondaparinux compared to enoxaparin in this setting.
Timepoint [1] 0 0
Until hospital discharge

Eligibility
Key inclusion criteria
1. Adult patients (18 years or over) admitted to the ICU and expected to stay for more
than 48 hours.

2. Patients who require continuous renal replacement therapy.

3. Patients who consent or if the patient is not competent, the next of kin who consent
to inclusion in the study. .

-
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patients aged less than 18 years of age.

2. Patients who are pregnant

3. Patients with a contraindication to anticoagulation for pre existing bleeding
diathesis

4. Patients or next of kin who do not consent to study inclusion. -

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2004
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2007
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
The Royal Melbourne Hospital Intensive Care Unit Grattan Street - Parkville
Recruitment postcode(s) [1] 0 0
3050 - Parkville

Funding & Sponsors
Primary sponsor type
Other
Name
Melbourne Health
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new
drug to prevent blood clotting in the continuous dialysis machine used in intensive care
patients who have kidney failure.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00256100
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
John F Cade
Address 0 0
Melbourne Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00256100